Clarigent Health utilizes vocal biomarker analysis through its Clairity platform to detect early signs of mental health conditions such as depression, anxiety, and suicide risk. This technology provides objective assessments that can be integrated into existing mental health services, addressing the critical gap in timely access to mental health care.
Funding
Funding not disclosed
Founders
Product
Problem
Mental healthcare faces challenges in early detection and timely access to services, leading to delayed interventions for conditions like depression, anxiety, and suicide risk. Traditional mental health assessments often lack objective measures, hindering accurate and consistent evaluations. The average wait time to access behavioral health services can be weeks or even months.
Solution
Clarigent Health's Clairity platform employs vocal biomarker analysis to provide objective assessments of mental health conditions. The technology analyzes speech patterns to detect subtle indicators of depression, anxiety, and suicide risk, similar to how medical imaging provides biomarkers for physical health. Clairity can be used as a stand-alone tool or integrated into existing mental health services, including telehealth platforms, primary care settings, and employee assistance programs. The platform aims to improve access to mental healthcare by identifying risks that may be missed by other methods.
Target Audience
The primary users are mental health professionals, primary care physicians, and organizations offering mental health services, such as telehealth providers, EAPs, and schools.
Features
- Vocal biomarker analysis to detect early signs of mental health conditions
- Virtual agent interface accessible on PCs, tablets, and smartphones
- Integration with telehealth platforms, primary care, EAPs, and school/community screenings
- Identification of risks potentially missed by other assessment methods
- Backed by almost 20 years of clinical research